Skip to content
TheChatArchiveThe Chat Archive
Grok 4.1 Fast· xaiHugging Face Frontier Reasoning Traces

Develop an inpatient venous thromboembolism prevention protocol: risk stratification,…

  1. User

    Develop an inpatient venous thromboembolism prevention protocol: risk stratification, pharmacologic vs mechanical prophylaxis, contraindication management, monitoring, and discharge instructions.

  2. Assistant

    Inpatient Venous Thromboembolism (VTE) Prevention Protocol

    Purpose: To standardize VTE prophylaxis for hospitalized adult patients (medical and surgical) to reduce risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), per ACCP/CHEST 2021 guidelines, ASH 2020, and hospital quality metrics.

    Scope: All non-ICU inpatients ≥18 years. ICU patients follow separate protocol. Obstetrics/pediatrics excluded.

    Implementation:

    • VTE Risk Assessment (RA) completed within 24 hours of admission and q72h or change in status (e.g., surgery, immobility).
    • Nursing/physician co-responsible. Document in EHR VTE flow sheet.
    • Multidisciplinary VTE committee reviews compliance quarterly.

    1. Risk Stratification

    Assess VTE risk (using Padua score for medical; Caprini for surgical) AND Bleeding risk (IMPROVE Bleed score). Scores available in EHR calculator.

    VTE Risk Categories

    Risk LevelPadua Score (Medical)Caprini Score (Surgical)Examples
    Low0–30–1Minor surgery, fully mobile
    Moderate4–High (≥4)2–4Acute MI, CHF, cancer, age ≥70, immobility
    High≥4 (with prior VTE) or very high≥5Prior VTE, thrombophilia, ortho/spine surgery, bariatric

    Bleeding Risk Categories

    Risk LevelIMPROVE Bleed ScoreExamples
    Low0–6No recent bleed, normal platelets/renal function
    High≥7Active bleed, platelets <50k, CrCl <30 mL/min, recent surgery/trauma/stroke, age ≥75 + anemia

    Overall Prophylaxis Decision: Use matrix below.

    2. Prophylaxis Recommendations

    Prophylaxis Matrix

    VTE Risk / Bleeding RiskLow BleedHigh Bleed
    Low VTENoneNone
    Moderate VTEPharmacologic (preferred) OR MechanicalMechanical (preferred) OR None if absolute contraindication
    High VTEPharmacologic (± Mechanical)Mechanical (± reassess pharma after 48h)
    • Preferred: Pharmacologic for moderate-high VTE/low bleed.
    • Mechanical alone: High bleed OR pharma contraindication.
    • No prophylaxis: Low VTE risk AND low bleed (reassess q72h).

    Pharmacologic Prophylaxis

    AgentStandard DoseAdjustmentsNotes
    Enoxaparin (LMWH)40 mg SQ q24h30 mg q24h if wt ≤50 kg or CrCl <30Preferred; renal-adjusted
    Heparin (UFH)5,000 units SQ q8h5,000 units SQ q12h if high bleed/renalAlternative if LMWH unavailable
    Fondaparinux2.5 mg SQ q24hAvoid if CrCl <30Use in HIT-suspect
    • Start within 24h of admission (12h post-op if low bleed).
    • Surgical: Omit 12–24h pre-op; resume 6–12h post-op.

    Mechanical Prophylaxis

    • Intermittent Pneumatic Compression Devices (IPCD): Preferred (arms/legs). Use 24h/day except ADLs/hygiene.
    • Graduated Compression Stockings (GCS): If IPCD contraindicated/unavailable (knee-high, 15–30 mmHg).
    • Combine with pharmacologic when possible.

    3. Contraindication Management

    Absolute Contraindications to Pharmacologic

    • Active bleed, ICH within 3 mo, epidural within 12h, platelets <20k, neurosurgery within 72h.
    • Management: Mechanical only. Reassess q24–48h.

    Relative Contraindications to Pharmacologic (High Bleed Risk)

    • Platelets 20–50k, recent GI/GU bleed, liver failure.
    • Management: Hold pharma; use mechanical. Restart when resolved (e.g., platelets >50k).

    Contraindications to Mechanical

    IPCDGCS
    - Severe PVD/ischemia- Fresh amputation- Skin breakdown- Paralysis/contractures- CHF (leg edema)- Same as IPCD- Arterial insufficiency (ABI <0.6)

    Management: No mechanical → early ambulation, pharmacologic if low bleed, or consult Hematology.

    Special Populations

    • Obese (BMI >40): Enoxaparin 0.5 mg/kg q24h.
    • CrCl 15–30: UFH preferred.
    • Cancer: LMWH preferred; consider DOAC outpatient.
    • Hip/Knee Arthroplasty: Continue 10–35 days post-discharge.
    • HIT History/Suspect: Avoid heparin; use fondaparinux or argatroban (therapeutic dose).

    4. Monitoring

    • Daily Nursing Assessment (EHR documentation):

      • VTE signs: Leg swelling/pain, dyspnea, chest pain.
      • Bleeding: Hb/Plt q24–48h initially, then q72h; inspect sites.
      • Mechanical: Skin integrity, fit, compliance (>80%).
      • HIT: Monitor Plt q2–3 days (4T score if drop >50%).
    • Physician Review: q72h or change (e.g., D-dimer if high suspicion; US/duplex if symptomatic).

    • Labs: CBC, Cr, PT/PTT baseline; aPTT not needed for prophylaxis.

    • Adverse Events:

      EventAction
      BleedingHold agent; transfuse prn; reverse with protamine (UFH/LMWH partial)
      HITStop heparin; start argatroban; confirm with serotonin assay
      Skin InjuryDiscontinue mechanical; wound care
    • Audit: 95% compliance target; report failures to VTE committee.

    5. Duration

    • Medical: Hospitalization or until fully mobile.
    • Surgical: 7–10 days (extend to 35 days for ortho, oncology, bariatric).
    • Reassess: q72h or discharge; wean if low risk.

    6. Discharge Instructions

    • Patient Education (verbal + handout/EHR):
      • Signs of VTE: Sudden leg pain/swelling, shortness of breath, chest pain, coughing blood → ER immediately.
      • Bleeding Signs: Unusual bruising, blood in stool/urine, severe headache → call MD/stop meds.
      • Medications: List agents/duration (e.g., enoxaparin 35 days post-hip replacement).
      • Lifestyle: Ambulate early, hydrate, avoid crossing legs, smoking cessation.
      • Follow-up: Clinic in 7–14 days; extended prophylaxis if high risk (e.g., cancer).
    • Prescriptions: Auto-generated for extended rx; LMWH self-injection teaching if outpatient.
    • High-Risk Referral: Hematology if prior VTE/thrombophilia.

    Approval: VTE Committee [Date].
    Revision: Annual or per new guidelines.
    Contact: Pharmacy (dosing), Hematology (complex cases).